Atovaquone enhances antitumor efficacy of TCR-T therapy by augmentation of ROS-induced ferroptosis in hepatocellular carcinoma

• Published in: Cancer Immunology, Immunotherapy Immunotherapy, 2024-02, Vol.73 (3), p.49-49, Article 49
• Main Authors: Chen, Anan, Yu, Zhiwu, Ma, Na, Lu, Xinyu, Zhang, Yajing, Xu, Weikang, Wang, Yiyue, Xie, Jiayi, Qin, Yuqi, Mo, Guoheng, Wu, Sha, Hou, Jinlin, Zhu, Wei
• Format: Article
• Language: English
• Subjects: Adoptive immunotherapy; Animals; Antitumor activity; Atovaquone; Atovaquone - pharmacology; Atovaquone - therapeutic use; Cancer Research; Carcinoma, Hepatocellular - therapy; Cell therapy; Cytotoxicity; Disease Models, Animal; Ferroptosis; Hepatocellular carcinoma; Humans; Immunology; Immunotherapy; L-Lactate dehydrogenase; Liver cancer; Liver Neoplasms - therapy; Lymphocytes; Lymphocytes T; Medicine; Medicine & Public Health; Mice; Oncology; Prospective Studies; Reactive Oxygen Species; Receptors, Antigen, T-Cell; T cell receptors; Tumor Microenvironment; Tumors; γ-Interferon
• ISSN: 1432-0851; 0340-7004; 1432-0851
• DOI: 10.1007/s00262-024-03628-2

T-cell receptor (TCR) engineered T-cell therapy has recently emerged as a promising adoptive immunotherapy approach for tumor treatment, yet hindered by tumor immune evasion resulting in poor therapeutic efficacy. The introduction of ferroptosis-targeted inducers offers a potential solution, as they empower T cells to induce ferroptosis and exert influence over the tumor microenvironment. Atovaquone (ATO) stands as a prospective pharmaceutical candidate with the potential to target ferroptosis, effectively provoking an excessive generation and accumulation of reactive oxygen species (ROS). In this study, we evaluated the effectiveness of a combination therapy comprising ATO and TCR-T cells against hepatocellular carcinoma (HCC), both in vitro and in vivo. The results of lactate dehydrogenase and cytokine assays demonstrated that ATO enhanced cytotoxicity mediated by AFP-specific TCR-T cells and promoted the release of IFN- γ in vitro. Additionally, in an established HCC xenograft mouse model, the combined therapy with low-dose ATO and TCR-T cells exhibited heightened efficacy in suppressing tumor growth, with no apparent adverse effects, comparable to the results achieved through monotherapy. The RNA-seq data unveiled a significant activation of the ferroptosis-related pathway in the combination therapy group in comparison to the TCR-T cells group. Mechanistically, the synergy between ATO and TCR-T cells augmented the release of IFN- γ by TCR-T cells, while concurrently elevating the intracellular and mitochondrial levels of ROS, expanding the labile iron pool, and impairing the integrity of the mitochondrial membrane in HepG2 cells. This multifaceted interaction culminated in the potentiation of ferroptosis within the tumor, primarily induced by an excess of ROS. In summary, the co-administration of ATO and TCR-T cells in HCC exhibited heightened vulnerability to ferroptosis. This heightened susceptibility led to the inhibition of tumor growth and the stimulation of an anti-tumor immune response. These findings suggest that repurposing atovaquone for adoptive cell therapy combination therapy holds the potential to enhance treatment outcomes in HCC.